Takeda’s/Sucampo Amitiza Gains IBS-C Indication
This article was originally published in PharmAsia News
Executive Summary
Takeda/Sucampo Pharmaceuticals' chronic idiopathic constipation drug Amitiza (lubiprostone) was approved by FDA April 29 for irritable bowel syndrome with constipation in women 18 years and older, making it the only drug available for IBS-C with a prescription